Obinutuzumab, a drug developed from the results of cancer immunology research at the University of Southampton, has been shown to reduce the risk of follicular lymphoma progression by an amazing 34%. Results were presented at the American Society of Hematology (ASH) congress.
Copy and paste this URL into your WordPress site to embed
